Phathom Pharmaceuticals, Inc. (PHAT) SEC Filings & Earnings Calls

Loss of NCE exclusivity would permit earlier ANDA approvals, reducing VOQUEZNA revenue and market share.

“BDR may succeed in its challenge ... which would result in a reduction in the period of regulatory exclusivity” · word for word

Litigation outcome uncertain; could negatively impact stock price and business prospects.

“developments in the litigation ... may hurt Phathom's stock price, VOQUEZNA sales, or Phathom's business” · word for word

Clinical trial risk: Phase 3 may fail to replicate Phase 2 results

“the Study may not replicate the results of Phathom’s Phase 2 study.” · word for word

Regulatory risk: FDA may not accept data for label expansion

“regulatory authorities may not agree that the results are sufficient to support a regulatory submission or approval of a label expansion.” · word for word

Long timeline to potential revenue: topline not until Q1 2028

“Topline results are expected in the first quarter of 2028.” · word for word

Revenue concentration on single product VOQUEZNA; any commercial or competitive setback could materially impact financials

“All revenue derived from VOQUEZNA; company is a single-product biopharma”

Gross-to-net discount guidance of 55-59% implies significant payer rebates and discounts, pressuring net revenue per prescription

“Guidance for gross-to-net discount (55-59%)” · word for word

Pipeline dependency on Phase 3 NERD and Phase 2 EoE trials; negative results could limit label expansion and growth potential

“Initiating Phase 3 NERD trial; Phase 2 EoE topline expected Q4 2026”

Customer concentration risk

“For the three and six months ended June 30, 2026, three customers accounted for 67% and 68% of product sales in each period, with each of these individual customers ranging from 20% to 24% of product sales.” · word for word

Supply chain disruption risk

“The Company had previously been informed by Sandoz that there could be a disruption in the supply of clarithromycin tablets, a component of the VOQUEZNA TRIPLE PAK, which could lead to a disruption in supply of the VOQUEZNA TRIPLE PAKs.” · word for word

High leverage and debt service risk

“Total debt, net of debt discount $ 164,587 (2026) vs $ 209,087 (2025) in thousands.”

Trial results are not yet known; forward-looking statements highlight risks of negative or mixed results.

“Phathom may receive negative or mixed results from the Study that are not sufficient to advance the program.”

Revenue concentration on single product VOQUEZNA; seasonal health plan access dynamics; competitive PPI market.

“First quarter reflected seasonal health plan access dynamics and was a bit light to internal expectations” · word for word

Customer concentration

“For the three months ended March 31, 2026, three customers accounted for 70% of the product sales in each period, with each of these individual customers ranging from 20% to 26% of the product sales.” · word for word

Supply chain disruption for VOQUEZNA TRIPLE PAK

“The Company had previously been informed by Sandoz that there could be a disruption in the supply of clarithromycin tablets, a component of the VOQUEZNA TRIPLE PAK, which could lead to a disruption in supply of the VOQUEZNA TRIPLE PAKs. Given more recent communications, however, the Company does not currently anticipate any near-term disruptions.” · word for word

High leverage and debt covenants

“The Loan Agreement contains customary closing fees, prepayment fees and provisions, events of default, and representations, warranties and covenants, including financial covenants.” · word for word

Dependence on single product

“We currently depend entirely on the success of our approved VOQUEZNA products, and in particular on the success of VOQUEZNA for the treatment of GERD.” · word for word

Need for additional financing

“We may require additional financing to achieve our goals, finance our operations and meet our financial obligations, and a failure to obtain this necessary capital when needed on acceptable terms, or at all, could force us to delay, limit, reduce or terminate our commercialization activities, product development programs, or other operations.” · word for word

Clinical trial failure

“We may not achieve favorable results in our ongoing clinical trial of vonoprazan in the treatment of EoE or in future clinical trials of vonoprazan or of any other product candidate we may develop, or receive additional regulatory approvals on a timely basis, if at all.” · word for word

Reimbursement risk

“The successful commercialization of VOQUEZNA, Voquezna Dual Pak and VOQUEZNA TRIPLE PAK will depend in part on the extent to which private health insurers and governmental authorities establish and maintain coverage, adequate reimbursement levels and favorable pricing policies.” · word for word

Competition from generics and PCABs

“For the treatment of Erosive GERD and Non-Erosive GERD, VOQUEZNA primarily competes with generic PPIs marketed by multiple pharmaceutical companies in both the prescription and OTC markets.” · word for word

Dependence on VOQUEZNA for revenue; single product risk.

“Revenue entirely from VOQUEZNA; no other approved products mentioned.”

Debt repayment obligations and RIFA cash hold covenants starting October 2026.

“RIFA cash hold covenants begin in October 2026 and adjust over time based on formulas related to royalty amounts paid to date.” · word for word

Clinical trial risk for EoE program; topline results not expected until 2027.

“The Phase 2 pHalcon-EoE-201 trial evaluating VOQUEZNA in patients with Eosinophilic Esophagitis (EoE) is actively enrolling as planned. Topline results are anticipated in 2027.” · word for word

Dilution from equity offering and pre-funded warrants.

“Pre-funded warrant form included; potential dilution for existing shareholders.”

Preliminary results subject to audit adjustments

“Actual results may differ materially from these preliminary estimates” · word for word

Dependence on VOQUEZNA commercial success for profitability

“we may not achieve results, revenues or growth from commercialization of VOQUEZNA at the levels to enable us to meet our expectations as to operating profitability” · word for word

Clinical trial risk; topline results not expected until 2027

“Topline primary and secondary results are anticipated to be available in 2027.” · word for word

Dependence on VOQUEZNA for revenue; generic entry risk after 2032.

“Phathom expects New Chemical Entity (NCE) exclusivity for VOQUEZNA 10 mg and 20 mg tablets through May 2032.” · word for word

Customer Concentration Risk

“For the three and nine months ended September 30, 2025, three customers accounted for 70% of the product sales in each period, with each of these individual customers ranging from 22% to 25% of the product sales in both periods.” · word for word

Supply Chain Disruption Risk

“The Company had previously been informed by Sandoz that there could be a disruption in the supply of clarithromycin tablets, a component of the VOQUEZNA TRIPLE PAK. Given more recent communications, however, the Company does not currently anticipate any near-term supply issues.” · word for word

Debt Covenant Compliance Risk

“Based on the Company’s current revenue projections, the Company does not expect to meet the revenue threshold to draw the Sixth Tranche.” · word for word

Clinical-stage biopharma with no approved products; net loss continues.

“Net loss of $19.6 million in Q3 2025.”